DEERFIELD, Ill.--(BUSINESS WIRE)--Dade Behring Inc.(NASDAQ:DADE), the world’s largest company solely dedicated to clinical diagnostics, today announced that it has signed a license and cooperation agreement with Euro-Diagnostica, a company specializing in autoimmune disease testing, granting rights to Dade Behring for the use of cyclic citrullinated peptides (CCP). Euro-Diagnostica will contribute know-how and key raw materials for the development of an automated anti-CCP test for use on Dade Behring’s clinical laboratory instrumentation.
